TRACK-FA provides a world-first intensive effort to combine global expertise in Friedreich’s ataxia (FA) to track the neurobiological changes underlying disease progression and address the urgent need for clinical trial-ready biomarkers.
It brings together the expertise and resources of six international research teams, and industry partners who will provide input on study design, endpoints, and monitoring.
How will it help the FA community?
TRACK-FA aims to accelerate the discovery and approval of new treatments for FA by:
- Improving our understanding of brain and spinal cord changes in FA
- Delivering a set of clinical trial-ready biomarkers
- Developing a community database for ongoing research and discovery
University of Campinas
- A/Prof Marcondes França
- Dr Thiago Rezende
Monash University and Murdoch Children’s Research Institute
Overall coordinating site for TRACK-FA
- Prof Nellie Georgiou-Karistianis
- A/Prof Louise Corben
- Prof Martin Delatycki
- Dr Ian Harding
RWTH Aachen University
- Prof Kathrin Reetz
- Prof Jörg B. Schulz
- Dr Imis Dogan
- Dr Sandro Romanzetti
University of Florida
- Prof Sub Subramony
- Prof Thomas Mareci
- A/Prof Manuela Corti
University of Minnesota
Oversee design and execution of the neuroimaging component of TRACK‐FA
- A/Prof Pierre‐Gilles Henry
- A/Prof Christophe Lenglet
Children’s Hospital of Philadelphia
- Prof Timothy Roberts
- Prof William Gaetz
- Prof David Lynch
- Prof Massimo Pandolfo
- Dr Alain Dagher
- A/Prof David Rudko
Our study sponsor - FARA
The Friedreich’s Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), non-profit, tax-exempt organisation dedicated to the pursuit of scientific research leading to treatments and a cure for FA.
FARA’s mission is to marshal and focus the resources and relationships needed to cure FA by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organisations dedicated to curing FA and related diseases.
Our contract research organisation - IXICO
IXICO is a premier neuroimaging provider, working with pharma and biotech partners to improve the outcomes of clinical trials.
Our industry partners
Takeda Pharmaceuticals is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide.
Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases.
PTC Therapeutics is bringing moments to patients with rare and serious diseases through innovative small molecule and gene therapies